Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of rebamipide 2% suspension for the treatment of patients with dry-eye.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Acucela Inc.; Kubota Vision Inc.
• Collaborator: Otsuka Pharmaceutical Co., Ltd.
• Treatments: Ophthalmic Solutions; Rebamipide; Tetrahydrozoline

Criteria

Inclusion Criteria:

• Age 18 years and older

• Diagnosis of dry eye as defined by the protocol

Exclusion Criteria:

• Ongoing ocular disease that may interfere with study parameters.

• Inability to stop using topical ophthalmic medications throughout the duration of the study

• Inability to stop the use of contact lenses for the duration of the study.